TAUVID (flortaucipir f-18)
TAUVID (flortaucipir F-18) is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) imaging of the brain. It is used to estimate the density and distribution of aggregated tau neurofibrillary tangles in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease. This imaging tool assists in the evaluation of a key neuropathological component of the disease, though it is not indicated for use in patients being evaluated for chronic traumatic encephalopathy.
How TAUVID Works
Flortaucipir F 18 functions by binding to aggregated tau protein, which combines to form neurofibrillary tangles in the brains of patients with Alzheimer's disease. The agent specifically binds to paired helical filament tau and is differentially retained in neocortical areas containing these aggregates. This retention allows for the visualization of tau distribution via PET imaging, though the agent may also exhibit off-target binding to monoamine oxidase-A and monoamine oxidase-B.
Details
- Status
- Prescription
- First Approved
- 2020-05-28
- Patent Cliff
- 2032
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
TAUVID Approval History
What TAUVID Treats
3 indicationsTAUVID is approved for 3 conditions since its original approval in 2020. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Alzheimer's Disease
- Chronic Traumatic Encephalopathy
- Cognitive Impairment
TAUVID Target & Pathway
ProTarget
TAUVID Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to TAUVID
3 of 10FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TAUVID FDA Label Details
Indications & Usage
FDA Label (PDF)TAUVID is indicated for the treatment of Alzheimer's Disease; Chronic Traumatic Encephalopathy; Cognitive Impairment.
TAUVID Patents & Exclusivity
Patents (1 active)
Pro Intelligence Preview
Deep insights for TAUVID
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2032
- • 16 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 10 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Related Intelligence
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.